公司资料
Jazz Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- JAZZ
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Ireland
股票表现
248.36 USD (+1.39%)
收盘价
最后更新: 2026年8月17日
14.2B USD
市值
股价为何变动
As of Aug 17, 2026, JAZZ closed up 1.39% at $248.36. No new same-company headline was identified in the current news window.
公司概览
业务概览
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience, oncology, and sleep disorder therapies. Its portfolio mixes established commercial products with development programs aimed at extending the company’s specialty franchise.
所在地与行业分类
Headquartered in Ireland and listed on NASDAQ, Jazz has a global commercial footprint and a specialty-pharma identity. It sits in neuroscience and oncology rather than broad pharma.
商业模式特征
The company generates value through specialty product sales, lifecycle management, and pipeline development in difficult-to-treat diseases. Investors watch revenue durability, patent and label risk, and the progress of new assets.
生物医药行业定位
Jazz occupies a steady specialty-biopharma position with catalyst sensitivity around pipeline and label updates. It is more commercial than a pure development-stage biotech name but still reacts to program milestones.
未来催化剂
- Jazz Pharmaceuticals’ catalysts are Xywav and oncology franchise execution, plus any pipeline update that extends the sleep-and-cancer mix. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。